As of August 15, 2026, the peptides with the clearest legal prescribing path are FDA-approved tesamorelin (Egrifta) and the Category 1 compounding substances sermorelin and ipamorelin. BPC-157, TB-500, KPV, MOTS-c, Epitalon, and Semax are not eligible for patient-specific compounding — but that picture is actively shifting: at its July 23–24 meeting the FDA’s advisory committee voted to recommend all six for the 503A list, against the agency’s own staff position. A recommendation is not a rule, so nothing has changed for patients yet. This page is on a 30-day re-verification cycle while FDA action is pending (last re-verified August 15, 2026); the FDA’s published lists are the authoritative source.
Which peptides are legal to prescribe right now
Three have a clear path. Tesamorelin is FDA-approved as Egrifta, so it is a fully legal prescription drug; compounded versions are also prepared by licensed pharmacies. Sermorelin (a GHRH analog once FDA-approved as Geref) and ipamorelin are classified Category 1 — 503A compounding pharmacies may prepare them under a valid, patient-specific prescription while the FDA completes its review.
Which peptides are still restricted
The peptides most discussed online — BPC-157, TB-500, KPV, and MOTs-C — are still not eligible for 503A patient-specific compounding. Their category status has a wrinkle worth stating precisely: in April 2026 the FDA removed the peptides under review from Category 2 (the restricted list), but it never placed them in Category 1 (the list that permits interim compounding) — so they sit in neither category, and compounding them remains unauthorized. The FDA’s Pharmacy Compounding Advisory Committee (PCAC) reviewed those four on July 23, 2026, with Emideltide (DSIP), Epitalon, and Semax following on July 24: Epitalon and Semax were recommended, while emideltide was the meeting’s only rejection, by a single vote.
What happened at the July 23–24, 2026 meeting
The FDA’s own briefing documents proposed that none of the seven peptides be added to the 503A Bulks List, citing insufficient effectiveness and safety evidence and incomplete physical and chemical characterization.
The committee did not follow that advice. On day one it voted to recommend BPC-157 (eight in favor, six against, one abstention), KPV (8–6), TB-500 (8–6), and MOTS-c (7–5); on day two it recommended Epitalon and Semax by similarly narrow margins, while emideltide (DSIP) became the only rejection of the meeting — by a single vote. Six of seven peptides cleared the committee, each over the written objection of the FDA’s review scientists. Members voting yes largely framed it as harm reduction: patients are already sourcing these peptides from the unregulated gray market, and supervised compounding is the safer of two imperfect options. Reporting on the session also noted that many yes votes came from committee members who represent or advise telehealth companies, an industry with a direct commercial stake in peptide access. For the fuller account, see our peptide therapy news explainer.
What “reclassification” does and does not mean
A February 2026 HHS announcement raised expectations that roughly 14 restricted peptides would return to Category 1, and in April 2026 the FDA did remove the peptides under review from Category 2. That drove a lot of headlines — but removal from the restricted list is not placement on the permitted one, and the July committee vote moved six peptides closer without changing the rule. Three things are worth holding separately:
- A PCAC recommendation is advisory only. The FDA decides, and here that would mean reversing its own scientists’ published position.
- Formal notice-and-comment rulemaking — a proposed rule, a comment period, then a final determination — is what actually changes the list, and legal analysts expect the process could extend into 2027 or 2028. The FDA also has five more peptides (GHK-Cu, Dihexa acetate, Cathelicidin LL-37, PEG-MGF, and Melanotan II) scheduled for committee review before the end of February 2027.
- Category 1 is not FDA approval. It only permits compounding under interim policy. FDA approval requires clinical trials and a New Drug Application. Compounded medications are not FDA-approved finished products.
Practically: if a seller cites the July 2026 vote as evidence that BPC-157 is now legal to buy, that is running ahead of the rule. For the full breakdown of that vote — the tallies, the 503A pathway, and the rulemaking timeline — see is BPC-157 legal now?
What this means if you are considering peptides
The honest read: work with a licensed clinician and a legitimate pharmacy, and start with peptides that have a real legal pathway today — the sermorelin vs tesamorelin decision is where most people begin. Treat any provider offering restricted peptides through a research-chemical route without clinical oversight as a warning sign, not a bargain — see compounded peptides vs research chemicals.
Compounded medications are prescribed and prepared by state-licensed, FDA-regulated compounding pharmacies. They are not FDA-approved finished products, and nothing here is a promise of results. Peptide use is decided within a licensed clinical relationship, and regulatory status changes — verify current FDA listings before acting.
Frequently asked questions
What peptides can I legally get prescribed in 2026? Tesamorelin (FDA-approved), plus sermorelin and ipamorelin (Category 1, compoundable under prescription while reviewed).
Is BPC-157 legal to prescribe? Not yet — it is off Category 2 (since April 2026) but was never added to Category 1 or the 503A list. The July 23, 2026 committee vote (8–6, one abstention) recommended listing it, but that is advisory only and the FDA has not acted; rulemaking could extend into 2027 or 2028.
Didn’t the FDA make 14 peptides legal? That was expected after a Feb 2026 announcement but has not become a rule. The July meeting recommended six of seven reviewed peptides — BPC-157, KPV, TB-500, MOTS-c, Epitalon, and Semax, with emideltide the sole rejection — a step, not a final decision.
Category 1 vs Category 2? Category 1 may be compounded under prescription during review; Category 2 may not.
Does Category 1 mean safe and effective? No — it is an interim compounding status, not an FDA efficacy determination.
Sources
- FDA, “July 23–24, 2026 Meeting of the Pharmacy Compounding Advisory Committee,” agenda and briefing documents, docket FDA-2025-N-6895 (fda.gov), captured 2026-07-23; re-verified 2026-08-15.
- McDermott Will & Emery, “Bulk-list bound? PCAC backs majority of peptides in two-day public meeting” (mcdermottlaw.com) — full two-day tallies including Epitalon, Semax, and the emideltide rejection, captured 2026-08-15.
- Sheppard Mullin, “Compounded Peptides on the Loose: What the Recent PCAC Meeting Means for Industry” (sheppard.com) — non-binding status and 2027–2028 rulemaking outlook, captured 2026-08-15.
- FDA Federal Register notice of April 16, 2026 announcing the PCAC meeting and Category 2 removal of the peptides under review, via FDA Law Blog coverage below, re-verified 2026-08-15.
- Contemporaneous reporting on the July 23, 2026 PCAC session — the 8–6–1 BPC-157 vote, the KPV vote, member rationale, and committee-member affiliations (STAT), captured 2026-07-23.
- FDA Law Blog, “FDA’s Pep(tide) Rally,” 2026-04 (thefdalawblog.com), on PCAC process and rulemaking timelines.
- OpenLoop Health, “What Peptides Are Becoming Legal in 2026?” and peptide FDA status trackers (openloophealth.com; newtropin.com), captured 2026-07-23.
- AgeMD, “BPC-157 FDA Status 2026” (agemd.com), captured 2026-07-23.